Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration

Simple item page
dc.contributor.authorKantor, Rami
dc.contributor.authorKatzenstein, David A
dc.contributor.authorEfron, Brad
dc.contributor.authorCarvalho, Ana Patricia
dc.contributor.authorWynhoven, Brian
dc.contributor.authorCane, Patricia
dc.contributor.authorClarke, John
dc.contributor.authorSirivichayakul, Sunee
dc.contributor.authorSoares, Marcelo A
dc.contributor.authorSnoeck, Joke
dc.contributor.authorPillay, Candice
dc.contributor.authorRudich, Hagit
dc.contributor.authorRodrigues, Rosangela
dc.contributor.authorHolguin, Africa
dc.contributor.authorMorris, Lynn
dc.contributor.authorVandamme, Anne-Mieke
dc.contributor.authorTanuri, Amilcar
dc.contributor.authorPhanuphak, Praphan
dc.contributor.authorWeber, Jonathan N
dc.contributor.authorPillay, Deenan
dc.contributor.authorHarrigan, Richard P
dc.contributor.authorCamacho, Ricardo
dc.contributor.authorSchapiro, Jonathan M
dc.contributor.authorShafer, Robert W
dc.date.accessioned2024-05-23T23:49:34Z
dc.date.available2024-05-23T23:49:34Z
dc.date.issued2005-04-26
dc.descriptionFil: Kantor R. Division of Infectious Disease and Center for AIDS Research, Stanford University, Stanford, California; USAes_ES
dc.description.abstractBackground The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate. Methods and Findings To assess the impact of HIV-1 subtype and antiretroviral treatment on the distribution of mutations in protease and reverse transcriptase, a binomial response model using subtype and treatment as explanatory variables was used to analyze a large compiled dataset of non-subtype-B HIV-1 sequences. Non-subtype-B sequences from 3,686 persons with well characterized antiretroviral treatment histories were analyzed in comparison to subtype B sequences from 4,769 persons. The non-subtype-B sequences included 461 with subtype A, 1,185 with C, 331 with D, 245 with F, 293 with G, 513 with CRF01_AE, and 618 with CRF02_AG. Each of the 55 known subtype B drug-resistance mutations occurred in at least one non-B isolate, and 44 (80%) of these mutations were significantly associated with antiretroviral treatment in at least one non-B subtype. Conversely, of 67 mutations found to be associated with antiretroviral therapy in at least one non-B subtype, 61 were also associated with antiretroviral therapy in subtype B isolates. Conclusion Global surveillance and genotypic assessment of drug resistance should focus primarily on the known subtype B drug-resistance mutations.es_ES
dc.formatapplication/pdfes_ES
dc.identifier.doihttps://doi.org/10.1371/journal.pmed.0020112
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1375
dc.languageENGes_ES
dc.provenancePublishedes_ES
dc.relation.ispartofseriesPLoS Medicine;2005 Apr;2(4):e112
dc.rightsopenAccesses_ES
dc.subjectHIV-1es_ES
dc.subjectAntiretroviral Therapy, Highly Activees_ES
dc.titleImpact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaborationes_ES
dc.typeArticuloes_ES

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
10.1371journal.pmed.0020112.pdf
Size:
728.71 KB
Format:
Adobe Portable Document Format
Description:
10.1371/journal.pmed.0020112_eng
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Articulos científicos